Shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) have been given a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus target price of $35.67 for the company and are anticipating that the company will post ($0.36) earnings per share for the current quarter, according to Zacks. Zacks has also given Dova Pharmaceuticals an industry rank of 185 out of 265 based on the ratings given to its competitors.
DOVA has been the topic of several research reports. Zacks Investment Research upgraded Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a research note on Wednesday, October 11th. Jefferies Group boosted their price target on Dova Pharmaceuticals to $33.00 and gave the company a “buy” rating in a research note on Tuesday, November 28th. Finally, BidaskClub lowered Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, January 5th.
Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). During the same period last year, the company posted ($0.41) earnings per share. equities analysts expect that Dova Pharmaceuticals will post -1.51 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of DOVA. California State Teachers Retirement System bought a new position in Dova Pharmaceuticals during the third quarter valued at about $202,000. Schwab Charles Investment Management Inc. bought a new position in Dova Pharmaceuticals during the third quarter valued at about $241,000. Bank of New York Mellon Corp bought a new position in Dova Pharmaceuticals during the third quarter valued at about $340,000. JPMorgan Chase & Co. bought a new position in Dova Pharmaceuticals during the second quarter valued at about $382,000. Finally, Vanguard Group Inc. acquired a new stake in Dova Pharmaceuticals during the second quarter valued at approximately $390,000. Hedge funds and other institutional investors own 26.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/05/brokerages-expect-dova-pharmaceuticals-inc-dova-to-announce-0-36-eps.html.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.